# EVA1A, a novel and promising prognostic biomarker in colorectal cancer

## TL;DR

This study explores EVA1A as a new biomarker for predicting poor outcomes in colorectal cancer patients.

## Contribution

EVA1A is identified as a novel independent prognostic biomarker for colorectal cancer.

## Key findings

- EVA1A expression is significantly higher in CRC tumor tissues compared to normal tissues.
- High EVA1A levels correlate with poor overall survival in CRC patients.
- EVA1A is an independent risk factor for CRC prognosis according to Cox analysis.

## Abstract

The purpose of this study was to investigate the potential of EVA1A as a prognostic biomarker for Colorectal cancer (CRC).

The study utilized public databases to analyze the difference in Evala mRNA expression between CRC tumor tissues and adjacent normal tissues. Additionallymunohistochemical staining was performed on 90 paired tissue samples to detect EVA1A expression. The relationship between EVA1A and clinicopathological features was examined, and a Kaplan-Meier survival analysis was conducted. Univariate and multivariate Cox analyses were employed to identify prognostic factors affecting the overall survival (OS) of CRC patients.

The analysis revealed a significant increase in Evala mRNA expression in CRC tumor cells compared to normal controls from public databases (P< 0.05). Immunohistochemical staining further confirmed a significant upregulation of EVA1A expression in CRC tissues (P< 0.05). High EVA1A expression was associated with age, pathological M stage, total tumor stage, and Carbohydrate antigen CA19-9 (CA19-9). Kaplan-Meier analysis demonstrated a significant association between high EVA1A expression and poor OS. Univariate and multivariate analysis identified EVA1A as an independent risk factor for CRC prognosis.

The study suggests that EVA1A is increased in CRC tumor tissues and may serve as a potential biomarker for poor prognosis in CRC.